Form 4: Akero Therapeutics Director Walmsley Reports Acquisition of Shares

Director G. Walmsley reports acquiring 200,000 shares of Akero Therapeutics, Inc. at $48 per share on January 30, 2025.

Summary

• On January 30, 2025, G. Walmsley, a director of Akero Therapeutics, Inc., acquired 200,000 shares of common stock at a price of $48 per share.
• Following the transaction, Walmsley indirectly owns 1,000,000 shares through Logos Global Master Fund LP and Logos Opportunities Fund IV LP.
• Walmsley also directly owns 2,168 shares of Akero Therapeutics common stock.
• The reporting person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.

Sentiment

Score: 6

Explanation: Neutral sentiment as it's a standard regulatory filing. The director's purchase is a potentially positive signal, but the filing itself is simply a disclosure.

Positives

• Director's purchase may signal confidence in the company's future prospects.

Industry Context

Form 4 filings are standard practice and provide transparency into the transactions of company insiders, allowing investors to track confidence levels and potential alignment of interests.

Stakeholder Impact

• Shareholders may view the director's purchase as a positive sign.

Key Dates

Keywords

Akero Therapeutics, Director, Share Acquisition, Form 4, AKRO, Beneficial Ownership, Securities